Viemed Healthcare, Inc. (VMD) SEC Filings & Earnings Calls

Insider selling via 10b5-1 plan

“Pursuant to the Trading Plan, Morgan Stanley Smith Barney LLC may sell up to 246,000 Common Shares of the Issuer held by MF LLC during the period beginning on the Selling Start Date, as determined under the Trading Plan, which will be no earlier than December 24, 2026, and ending November 30, 2027.” · word for word

Insider selling via 10b5-1 plan

“Pursuant to the Trading Plan, Morgan Stanley Smith Barney LLC may sell up to 246,000 Common Shares of the Issuer held by MF LLC during the period beginning on the Selling Start Date, as determined under the Trading Plan, which will be no earlier than December 24, 2026, and ending November 30, 2027.” · word for word

No new risk signals; boilerplate forward-looking statements.

“Standard risk factor language.”

Reimbursement Risk from CMS NCD

“The final NCD establishes specific medical necessity criteria for ventilator use that are expected to influence patient access, reimbursement, and utilization patterns.” · word for word

Cost Inflation Pressure

“Manufacturing and distribution expenses are influenced by factors such as rising material, labor, and transportation costs, including fuel.” · word for word

Payor Consolidation Pricing Pressure

“The consolidation of managed care payors into larger purchasing groups has increased negotiating power, resulting in pricing pressure on HME providers.” · word for word

Adjusted EBITDA declined YoY; prior year non-recurring gain masks underlying trend.

“Adjusted EBITDA -4% YoY; prior year included $1.0M non-recurring gain.”

Reimbursement policy risk from CMS NCD

“The final NCD establishes specific medical necessity criteria for ventilator use that are expected to influence patient access, reimbursement, and utilization patterns.” · word for word

Concentration risk from Medicare payor

“Revenues from Medicare as a percentage of the Company's total revenue for the three months ended March 31, 2026 and 2025 were 35 % and 41 %, respectively.” · word for word

Integration risk from acquisitions

“The increase was primarily attributable to growth in our women's health product offerings, including breast pumps and related accessories, driven largely by the inclusion of revenues from the Lehan acquisition” · word for word

Tariff and supply chain cost pressure

“While certain medical equipment and components have historically been excluded from tariff regimes or subject to exemptions, trade measures may be expanded, reclassified, or implemented with limited notice, and suppliers may increase prices to reflect higher input costs, compliance requirements, or logistics constraints.” · word for word

Sleep resupply patient count declined 8% sequentially, indicating potential churn or seasonality

“sleep resupply patient count was 33,661 as of March 31, 2026, an increase of 47% over March 31, 2025, and an 8% sequential decrease from December 31, 2025.” · word for word

Equity dilution from compensation plans

“the 7,696,717 Common Shares that will be reserved for issuance under the 2024 Omnibus Plan and the Prior Plans ... represents 20% of the total issued and outstanding Common Shares as of April 8, 2026” · word for word

Key person dependency on CEO and President

“Casey Hoyt ... 3,295,788 ... 8.6% ... Michael Moore ... 2,294,018 ... 6.0%”

Medicare Reimbursement Policy Change

“The final NCD establishes specific medical necessity criteria for ventilator use that are expected to influence patient access, reimbursement, and utilization patterns.” · word for word

Concentration Risk - Ventilator Revenue

“Monthly rental revenue from ventilators represented approximately 51% and 56%, respectively, of revenue for 2025 and 2024.” · word for word

Regulatory Accreditation Changes

“Beginning in 2027, Viemed’s business locations will be subject to new, unannounced accreditation surveys and reaccreditation processes every 12 months.” · word for word

Dependence on organic growth and acquisition integration

“Growth includes contributions from 2025 acquisition of Lehan's Medical Equipment”

No material new risks; extension suggests proactive liquidity management.

“Extension of delayed draw term loan commitment expiration date.”

Revenue guidance narrowed to $271-273M from $271-277M, implying a slight reduction in the upper end, though EBITDA guidance was raised.

“Net Revenue guidance: $271M to $273M (prev $271M to $277M).”

Acquisition integration risk from Lehan's Medical Equipment acquisition, though it was immediately accretive.

“Acquisition of Lehan's Medical Equipment closed July 1, 2025; results included since acquisition date.”

Reimbursement Risk from CMS NCD

“The final NCD establishes specific medical necessity criteria for ventilator use that are expected to influence patient access, reimbursement, and utilization patterns.” · word for word

Cost Inflation Pressure

“Manufacturing and distribution expenses are influenced by factors such as rising material, labor, and transportation costs, including fuel.” · word for word